Opening book details…
Can I read Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up on EtoBox?
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up by S.P. D'Angelo; S. Bhatia; A.S. Brohl; O. Hamid; J.M. Mehnert; P. Terheyden; K.C. Shih; I. Brownell; C. Lebbé; K.D. Lewis; G.P. Linette; M. Milella; H. Xiong; G. Guezel; P.T. Nghiem is a Medicine article available to read on EtoBox.
What is Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up about?
## Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic MCC (mMCC), based on efficacy and safety data observed in the JAVELIN Merkel 200 trial. We report long-term overall survival (OS) data after >5 years of follow-up from the cohort of patients with mMCC whose disease had progressed after one or more prior lines of chemotherapy. ## Patients and methods In Part A of the single-arm, open-label, phase II JAVELIN Merkel 200 trial, patients with mMCC that had progressed following one or more prior lines of chemotherapy received avelumab 10 mg/kg by intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. In this analysis, long-term OS was analyzed. ## Results In total, 88 patients were treated with avelumab. At data cut-off (25 September 2020), median follow-up was 65.1 months (range 60.8-74.1 months). One patient (1.1%) remained on treatment, and an additional patient (1.1%) had reinitiated avelumab after previously discontinuing treatment
Who reads Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- S.P. D'Angelo; S. Bhatia; A.S. Brohl; O. Hamid; J.M. Mehnert; P. Terheyden; K.C. Shih; I. Brownell; C. Lebbé; K.D. Lewis; G.P. Linette; M. Milella; H. Xiong; G. Guezel; P.T. Nghiem
- Publisher
- Elsevier BV
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)